Mantle cell lymphoma is a rare type of blood cancer, which leads to the excessive growth of lymphocytes. It is one of the B-cell non-Hodgkin lymphoma, which occurs due to the formation of tumors in the lymph nodes, which enters the blood and spreads to the bone marrow, digestive tract, spleen, and liver. Loss of appetite, weight loss, fever, nausea, and vomiting are some of the common symptoms of mantle cell lymphoma. In 2012, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for bortezomib (Velcade), which updates the existing label to include a subcutaneous method of administration for the treatment of mantle cell lymphoma (MCL) patients who have received at least one prior therapy.
To get detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/ongoing-insight/toc/1148
Growing prevalence of mantle cell lymphoma is projected to augment the growth of the mantle cell lymphoma treatment market over the forecast period
Rising prevalence of mantle cell lymphoma and increasing research and development activities in the healthcare sector resulting in a promising product pipeline is a prime factor fueling the market growth. According to the study by Drug Development Technology, 2017, an estimated 3,300 new cases of mantle cell lymphoma are diagnosed every year in the U.S. The mantle cell lymphoma treatment market is projected to gain significant traction with the approval from the federal agencies. For instance, in October 2017, AstraZeneca received approval for Calquence under the FDA’s accelerated approval pathway for the treatment of adults with mantle cell lymphoma. Also, the development of targeted agents with low toxicity profiles for the treatment of relapsed mantle cell lymphoma in combination with approved drugs is also a major factor augmenting the mantle cell lymphoma treatment market growth. On the other side, serious side effects associated with the use of drugs such as anemia, neutropenia, and diarrhea are the factors restraining the growth of the mantle cell lymphoma treatment market.
The global mantle cell lymphoma treatment market is segmented on the basis of therapy type, route of administration, end-user, and geography.
On the basis of therapy type
- Monoclonal Antibody Therapy
- Targeted Therapy
- Stem Cell Treatment
On the basis of the route of administration:
On the basis of the end-user
- Ambulatory Surgical Centers
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1148
Rising approval pathway program by the U.S. FDA is projected to propel the mantle cell lymphoma treatment market in North America
Regional segmentation of the mantle cell lymphoma treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is projected to be dominant in the global market over the forecast period and this can be attributed to the increasing incidence rate of the disease in the region. According to the Leukemia and Lymphoma Society, 2014, about 70,800 new cases of non-Hodkin Lymphoma were registered in the U.S., where mantle cell lymphoma represented about 6% or 4,200 cases of the total cases. Also, the FDA’s Center for Drug Evaluation and Research Agency works with manufacturers to analyze drug development, approval, promising the Breakthrough Therapy Destination Program to make treatments available for patients with rare diseases. For instance, in 2013, the FDA approved Imbruvica (ibrutinib), manufactured by Janssen Pharmaceuticals, Inc. as a breakthrough therapy destination to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. The Asia Pacific is projected to witness a high growth rate in the mantle cell lymphoma treatment market over the forecast period due to rising government initiatives, an increase in research and development to curb the disease.
Key players are offering products to cater to unmet needs in patients with relapsed or refractory mantle cell lymphoma. For instance, Kite Pharma, Inc. is focused on developing engineered autologous T cell therapy products for the treatment of cancer. In 2015, the company initiated Phase 2 clinical study of KTE-C19 in patients with relapsed or refractory mantle cell lymphoma.
Key players operating in the global mantle cell lymphoma treatment market include F.Hoffman La Roche Ltd., Abbvie, Inc., Kite Pharma, Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, GlaxoSmithKline Plc, Amgen, Inc., Gilead Sciences, Inc., and Johnson and Johnson.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/1148
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027